REMEDIUM

Healthcare systems across the world are looking at ways of maintaining the continuity of supply of medicines to patients in times of crisis. Whilst this is not a new phenomenon, the additional burden placed on the supply chain during COVID-19 has meant it has come more into the spotlight. The need to use a stockpile can be caused by an interruption to supply, a rapid and unexpected peak in demand, or when both an interruption to supply and a peak in demand occur simultaneously. The objectives of a stockpile will guide the portfolio breadth and depth

Китайские ученые выяснили, что урсодезоксихолевая кислота (УДХК), традиционно используемая в лечении заболеваний печени, обладает способностью снижать воспаление дыхательных путей и служить средством профилактики развития воспалительного процесса и фиброза легких.

The atrial fibrillation (AF) is detected in almost 2% of the general population, and its prevalence is continuously rising as the population is aging. Stroke is the most severe complication of AF and its risk can be significantly reduced by using oral anticoagulants [1].

Atrial fibrillation (AF) is the most common arrhythmia that can be complicated by stroke at the 1 to 30% credible level per year in the absence of anticoagulant therapy, depending on the risk factor profile. Numerous clinical studies have strongly confirmed the efficacy of antithrombotic therapy, mainly with anticoagulants, in patients with AF [1].

Introduction. Pregnant women may be at increased risk for severe COVID-19 illness. Pregnant women are more likely to be hospitalized at ICU, needed the mechanical ventilation compared to nonpregnant women. The pregnant women are currently excluded from the most of the clinical trials of COVID-19 drug therapy. This limits the formulation of appropriate recommendations for the treatment of pregnant women with SARS-CoV-2 infection. Building on the experience of the effective use of surfactant therapy for influenza A/H1N1 treatment of pregnant women with COVID-19, the domestic/local drug Surfactant BL was included in the complex therapy.The objective. To evaluate the effectiveness of surfactant therapy in the integrated treatment of severe COVID-19 pneumonia of pregnant women and postpartum women.Materials and methods. The study included 69 pregnant and postpartum women with severe COVID-19 pneumonia. All ofthem received antiviral, anticoagulant and anti-inflammatory therapy. 47 patients (group 1) with an initially more severe course of the disease received inhalations with Surfactant BL in 1-2 days after admission to the intensive care unit, 22 patients (group 2) were prescribed surfactant therapy for 4-5 days, due to the progression of respiratory failure. Surfactant BL was administered at a dose of 75 mg 2 times a day through a nebulizer for 2-5 days. Result. In group 1 patients, SpO2 recovered faster and dyspnea decreased. All patients of group 1 did not require mechanical ventilation; in group 2, 3 patients (14.3%) required mechanical ventilation. In the group of early use of surfactant therapy with CT control, in most cases, there was a positive trend (67.6%), in contrast to group 2 (37.5%). Stay in ICU conditions in group 1 was 8.6 days, in group 2 - 13.2 days. No lethal outcomes were observed with surfactant therapy in both groups.

The article is devoted to the problems of legal regulation of pharmaceutical activities. The main contradictions of legislation in the approaches to the definition of the concepts of “pharmaceutical organization”, “subject of pharmaceutical activities”, “pharmacy organization”, “type of pharmacy organization” are considered. The problem of uncertainty in the status of a pharmacy organization, an individual entrepreneur with a pharmaceutical license has been identified. The need to develop an unified terminology for the types of pharmacy organizations, indicating their differences according to criteria such as functional purpose and structural features, is indicated. It was proposed to amend the Federal Law-61 taking into account the provisions of Federal Law-323, a new order “On the approval of the types of pharmaceutical organizations.”

Financial status is the most important characteristic of the economic activity of the industry enterprises, which determines its economic attractiveness. Let us consider a set of indicators reflecting the availability, placement and use of financial resources of enterprises in the industry. Financial status of the industry enterprises is analysed using the data form State Statistical Reporting Form No. P-3 Information on Company Financial Status.

Производство медицинской продукции за октябрь 2020 года Фармацевтическая реклама ЛП и БАД в российских СМИ в ноябре 2020 года ТОП-20 крупнейших рекламодателей и рекламируемых марок ЛП и БАД в Российских СМИ* в ноябре 2020 года